RET and paraganglioma: Germline genetic testing for these hereditary syndromes has historically been pursued when an individual’s personal and/or self-reported family history is suggestive of the condition (e.g., RET sequencing when a person is diagnosed with medullary thyroid cancer or SDHx testing after a paraganglioma of the head or neck is diagnosed), as the presence of a P/LP variant informs additional tumor risks, guides risk management, and enables testing of at-risk relatives [5, 21–24].